Malaysian Patent Granted for CytoMed Therapeutics’ Licensed Allogeneic CAR-Gamma Delta T Cell Technology
SINGAPORE, Jan. 29, 2024 (GLOBE NEWSWIRE) — CytoMed Therapeutics Limited (NASDAQ:GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based immunotherapies for the treatment of various cancers, announced today that the Intellectual Property Corporation of Malaysia has granted a patent for its chimeric antigen receptor gamma delta T cell (“CAR-γδ T cell”) technology, which targets solid and hematological tumors.
Related news for (GDTC)
- CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
- CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders
- CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India
- 24/7 Market News Snapshot 06 January, 2025 – CytoMed Therapeutics Limited Ordinary Shares (NASDAQ:GDTC)
- Update on Clinical Milestone – CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies